Acumen Pharmaceuticals (ABOS) Financial Statements
Price: $0.9008
Market Cap: $54.56M
Avg Volume: 242.80K
Market Cap: $54.56M
Avg Volume: 242.80K
Country: US
Industry: Biotechnology
Sector: Healthcare
Industry: Biotechnology
Sector: Healthcare
Overview of Financial Statements
Financial statements are records that provide an overview of a company's financial performance and position. There are three main types of financial statements:
- Income Statement: Shows the company's revenue, expenses, and profit over a specific period.
- Balance Sheet: Provides a snapshot of the company's assets, liabilities, and equity at a specific point in time.
- Cash Flow Statement: Details the cash inflows and outflows from operating, investing, and financing activities over a period.
This page presents both annual and quarterly data for these financial statements. The charts below provide a visual representation of the key metrics from each statement, helping you to quickly understand the financial health of Acumen Pharmaceuticals.
Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $1.44M | $1.70M |
| Cost of Revenue | $- | $184.00K | $169.00K | $4.00K | $8.00K | $8.58K |
| Gross Profit | $- | $-42.32M | $-169.00K | $-4.00K | $1.43M | $1.69M |
| Gross Profit Ratio | 0.00% | - | - | - | 99.44% | 99.49% |
| Research and Development Expenses | $93.80M | $42.32M | $32.36M | $12.30M | $8.00M | $8.58M |
| General and Administrative Expenses | $20.22M | $18.82M | $12.88M | $7.28M | $1.35M | $926.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $20.22M | $18.82M | $12.88M | $7.28M | $1.35M | $926.00K |
| Other Expenses | $- | $-42.32M | $-11.00K | $51.00K | $- | $- |
| Operating Expenses | $114.02M | $61.14M | $45.24M | $19.58M | $9.35M | $9.50M |
| Cost and Expenses | $114.02M | $61.14M | $45.24M | $19.58M | $9.35M | $9.50M |
| Interest Income | $14.32M | $10.21M | $2.39M | $84.00K | $1.00K | $45.00K |
| Interest Expense | $4.07M | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $178.00K | $184.00K | $169.00K | $4.00K | $7.91M | $7.80M |
| EBITDA | $-98.08M | $-51.61M | $-42.69M | $61.58M | $587.00K | $119.00K |
| EBITDA Ratio | - | - | - | - | 40.88% | 7.01% |
| Operating Income | $-114.02M | $-61.14M | $-45.24M | $61.57M | $-7.91M | $-7.80M |
| Operating Income Ratio | - | - | - | - | -550.97% | -459.93% |
| Total Other Income Expenses Net | $11.69M | $8.77M | $2.38M | $-81.02M | $587.00K | $-102.00K |
| Income Before Tax | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M | $-7.91M |
| Income Before Tax Ratio | - | - | - | - | -510.10% | -465.94% |
| Income Tax Expense | $- | $- | $-2.38M | $81.07M | $-1.00K | $-45.00K |
| Net Income | $-102.33M | $-52.37M | $-40.48M | $-181.68M | $-7.32M | $-7.86M |
| Net Income Ratio | - | - | - | - | -510.03% | -463.29% |
| EPS | $-1.71 | $-1.08 | $-1.00 | $-4.49 | $-0.18 | $-0.20 |
| EPS Diluted | $-1.71 | $-1.08 | $-1.00 | $-4.49 | $-0.18 | $-0.20 |
| Weighted Average Shares Outstanding | 60.01M | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
| Weighted Average Shares Outstanding Diluted | 60.01M | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
| SEC Filing | Source | Source | Source | Source | Source | Source |
Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $35.63M | $66.89M | $130.10M | $122.16M | $43.78M | $6.55M |
| Short Term Investments | $135.93M | $176.64M | $47.50M | $72.08M | $- | $- |
| Cash and Short Term Investments | $171.56M | $243.52M | $177.60M | $194.24M | $43.78M | $6.55M |
| Net Receivables | $- | $225.00K | $- | $- | $109.00K | $30.00K |
| Inventory | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $6.75M | $2.87M | $2.72M | $4.42M | $543.00K | $1.14M |
| Total Current Assets | $178.31M | $246.62M | $180.33M | $198.66M | $44.43M | $7.18M |
| Property Plant Equipment Net | $339.00K | $503.00K | $270.00K | $36.00K | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $62.55M | $15.84M | $31.62M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $60.35M | $454.00K | $151.00K | $14.00K | $- | $144.00K |
| Total Non-Current Assets | $60.69M | $63.51M | $16.26M | $31.67M | $- | $144.00K |
| Other Assets | $- | $- | $- | $- | $- | $- |
| Total Assets | $238.99M | $310.12M | $196.59M | $230.33M | $44.43M | $7.32M |
| Account Payables | $5.65M | $1.38M | $1.64M | $1.09M | $531.00K | $223.00K |
| Short Term Debt | $133.00K | $1.73M | $210.00K | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $21.83M | $9.86M | $5.96M | $4.06M | $5.84M | $1.12M |
| Total Current Liabilities | $27.61M | $12.97M | $7.81M | $5.15M | $6.37M | $1.34M |
| Long Term Debt | $28.60M | $27.62M | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $970.00K | $2.56M | $- | $- | $56.65M | $17.40M |
| Total Non-Current Liabilities | $29.57M | $30.18M | $- | $- | $56.65M | $17.40M |
| Other Liabilities | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $57.18M | $43.15M | $7.81M | $5.15M | $63.02M | $18.74M |
| Preferred Stock | $- | $- | $- | $- | $- | $- |
| Common Stock | $6.00K | $6.00K | $4.00K | $4.00K | $- | $- |
| Retained Earnings | $-325.13M | $-222.80M | $-170.43M | $-127.57M | $-26.96M | $-19.64M |
| Accumulated Other Comprehensive Income Loss | $-48.00K | $312.00K | $-751.00K | $-231.00K | $- | $- |
| Other Total Stockholders Equity | $506.99M | $489.45M | $359.95M | $352.98M | $65.03M | $25.62M |
| Total Stockholders Equity | $181.82M | $266.97M | $188.78M | $225.18M | $-18.59M | $-11.42M |
| Total Equity | $181.82M | $266.97M | $188.78M | $225.18M | $-18.59M | $-11.42M |
| Total Liabilities and Stockholders Equity | $238.99M | $310.12M | $196.59M | $230.33M | $44.43M | $7.32M |
| Minority Interest | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $238.99M | $310.12M | $196.59M | $230.33M | $44.43M | $7.32M |
| Total Investments | $135.93M | $239.19M | $63.34M | $103.69M | $- | $- |
| Total Debt | $28.73M | $28.49M | $105.00K | $- | $- | $- |
| Net Debt | $-6.89M | $-38.40M | $-130.00M | $-122.16M | $-43.78M | $-6.55M |
Cash Flow Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M | $-7.91M |
| Depreciation and Amortization | $178.00K | $184.00K | $169.00K | $4.00K | $- | $- |
| Deferred Income Tax | $- | $- | $- | $155.00K | $- | $- |
| Stock Based Compensation | $9.63M | $6.14M | $3.06M | $922.00K | $154.00K | $174.00K |
| Change in Working Capital | $11.65M | $3.87M | $3.99M | $298.00K | $307.00K | $768.00K |
| Accounts Receivables | $- | $- | $- | $- | $-79.00K | $200.00K |
| Inventory | $- | $- | $- | $- | $79.00K | $-200.00K |
| Accounts Payables | $4.27M | $-261.00K | $552.00K | $557.00K | $308.00K | $110.00K |
| Other Working Capital | $7.38M | $4.13M | $3.43M | $-259.00K | $-1.00K | $658.00K |
| Other Non Cash Items | $-5.35M | $-888.00K | $487.00K | $81.27M | $-586.00K | $147.00K |
| Net Cash Provided by Operating Activities | $-86.22M | $-43.06M | $-35.15M | $-17.96M | $-7.45M | $-6.82M |
| Investments in Property Plant and Equipment | $-16.00K | $-21.00K | $-161.00K | $-40.00K | $- | $- |
| Acquisitions Net | $- | $- | $-39.35K | $- | $- | $- |
| Purchases of Investments | $-170.73M | $-250.63M | $-41.51M | $-104.08M | $- | $- |
| Sales Maturities of Investments | $218.77M | $78.98M | $80.86M | $- | $- | $- |
| Other Investing Activities | $- | $3.00K | $39.35K | $-104.08K | $- | $- |
| Net Cash Used for Investing Activities | $48.03M | $-171.67M | $39.19M | $-104.12M | $- | $- |
| Debt Repayment | $-739.00K | $30.00M | $- | $- | $- | $- |
| Common Stock Issued | $7.94M | $121.90M | $3.79M | $168.56M | $44.67M | $6.24M |
| Common Stock Repurchased | $-41.00K | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-230.00K | $-151.00K | $115.00K | $31.91M | $44.67M | $6.24M |
| Net Cash Used Provided by Financing Activities | $6.93M | $151.75M | $3.91M | $200.47M | $44.67M | $6.24M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-31.26M | $-62.98M | $7.94M | $78.39M | $37.23M | $-579.00K |
| Cash at End of Period | $35.86M | $67.12M | $130.10M | $122.16M | $43.78M | $6.55M |
| Cash at Beginning of Period | $67.12M | $130.10M | $122.16M | $43.78M | $6.55M | $7.13M |
| Operating Cash Flow | $-86.22M | $-43.06M | $-35.15M | $-17.96M | $-7.45M | $-6.82M |
| Capital Expenditure | $-16.00K | $-21.00K | $-161.00K | $-40.00K | $- | $- |
| Free Cash Flow | $-86.23M | $-43.09M | $-35.31M | $-18.00M | $-7.45M | $-6.82M |